Skip to main content

Table 2 Baseline and change in low-density lipoprotein particle size by end-of-treatment triglyceride category

From: Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

End-of-treatment TG category and Statin + OO Statin + OM3-CA Statin + OM3-CA
LDL particle size 4 g/d 2 g/da 4 g/d
  Mean (95 % CI)
TG <1.7 mmol/L (<150 mg/dL) (n = 15) (n = 14) (n = 33)
  Baseline LDL particle size (nm) 20.33 (20.09, 20.57) 20.10 (19.89, 20.31) 20.17 (20.03, 20.31)
  Δ from baseline LDL particle size (nm) 0.22 (0.03, 0.41) 0.15 (0.00, 0.30) 0.31 (0.17, 0.45)
TG 1.7–2.2 mmol/L (150–199 mg/dL) (n = 33) (n = 52) (n = 54)
  Baseline LDL particle size (nm) 20.12 (19.96, 20.28) 20.03 (19.95, 20.11) 20.05 (19.93, 20.17)
  Δ from baseline LDL particle size (nm) 0.09 (−0.03, 0.21) 0.10 (0.04, 0.16) 0.17 (0.09, 0.25)
TG ≥2.3 mmol/L (≥200 mg/dL) (n = 163) (n = 142) (n = 120)
  Baseline LDL particle size (nm) 19.87 (19.82, 19.92) 19.89 (19.83, 19.95) 19.82 (19.77, 19.87)
  Δ from baseline LDL particle size (nm) −0.05 (−0.09, −0.01) 0.05 (0.00, 0.10) 0.04 (0.00, 0.08)
  1. Abbreviations: change, CI confidence interval, LDL low-density lipoprotein, OM3-CA omega-3 carboxylic acids, OO olive oil, TG triglycerides
  2. aPatients in the OM3-CA 2 g/d treatment arm also received OO capsules at a dosage of 2 g/d